Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Breast cancer-specific survival in >4,600 patients with lymph node-positive (LN+) hormone receptor-positive (HR+) invasive breast cancer (BC) and 21-gene recurrence score® (RS) results in the SEER registries

Date

08 Oct 2016

Session

Breast cancer, early

Presenters

Dave Miller

Citation

Annals of Oncology (2016) 27 (6): 43-67. 10.1093/annonc/mdw364

Authors

D.P. Miller1, M. Roberts2, V.I. Petkov3, S. Shak1, N. Howlader3, K. Cronin3, L. Penberthy3

Author affiliations

  • 1 Translational Sciences, Genomic Health, Inc., 94063 - Redwood City/US
  • 2 Division Of Cancer Prevention, National Cancer Institute, Rockville/US
  • 3 Division Of Cancer Control And Population Sciences, National Cancer Institute, Rockville/US
More

Resources

Background

The 21-gene RS assay has been shown to predict BC recurrence and adjuvant chemotherapy benefit in LN + , HR + , HER2-negative BC. We assessed 5-year BC-specific survival (BCSS) in LN+ patients with 21-gene RS results in the SEER registries, a cancer surveillance program that covers 30% of the US population.

Methods

All SEER BC cases diagnosed 2004-2012 were linked to 21-gene assays performed by the Genomic Health Clinical Laboratory. The analysis was restricted to single primary invasive BC, LN + , no distant metastases, HR+ (per SEER), HER2-negative (per RT-PCR). Using the actuarial method in SEER*Stat, BCSS was assessed for those who were diagnosed 2004-2011 with survival follow-up through 2012, by RS category and by number of positive nodes.

Results

The proportion of women with LN + , HR+ BC who had RS results (n = 7695) increased over time between 2004 (0.3%, n = 33) and 2012 (13.8%, n = 2010), and was lower with increasing nodal involvement, from micrometastases only (36.0%, n = 792) to 4+ nodes (2.6%, n = 81) in 2012. BCSS differed significantly by both RS category (log-rank p 

Conclusions

Overall, 5-year BCSS is excellent in patients with RS

Clinical trial identification

N/A

Legal entity responsible for the study

Dave P. Miller, Megan Roberts, Lynne Penberthy

Funding

National Cancer Institute

Disclosure

D.P. Miller, S. Shak: Employed by Genomic Health; stock ownership in Genomic Health

All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings